Evidence map›Paper›PMID 40995433›Full record

ArticleFrontiers in genetics2025

Genetic heterogeneity in childhood leukemia/lymphoma: a Turkish cohort with strong predisposition.

Gizem Onder, Ozkan Ozdemir, Fulya Taylan, Cengiz Canpolat, Koray Yalcin, Fatih Erbey, Banu Oflaz Sozmen, Fikret Asarcikli, Turan Bayhan, Yunus Murat Akcabelen and 22 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Gizem OnderDepartment of Biochemistry and Molecular Biology, Health Sciences Institute, Acıbadem Mehmet Ali Aydınlar University, Istanbul, Türkiye.
Ozkan OzdemirRare Diseases and Orphan Drugs Application and Research Center (ACURARE), Rare Diseases and Orphan Drugs Application and Research Center (ACURARE), Acıbadem University, Istanbul, Türkiye.
Fulya TaylanDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Cengiz CanpolatDepartment of Pediatric Oncology, School of Medicine, Acıbadem Mehmet Ali Aydınlar University, Istanbul, Türkiye.
Koray YalcinDepartment of Pediatric Hematology, Bahçeşehir University, Goztepe Medical Park Hospital, Istanbul, Türkiye.
Fatih ErbeyDepartment of Pediatric Hematology and Oncology, Hospital of Koç University, Istanbul, Türkiye.
Banu Oflaz SozmenDepartment of Pediatric Hematology and Oncology, Hospital of Koç University, Istanbul, Türkiye.
Fikret AsarcikliDepartment of Pediatric Hematology and Oncology, Hospital of Koç University, Istanbul, Türkiye.
Turan BayhanDepartment of Pediatric Hematology and Oncology, Ankara Bilkent City Hospital, Ankara, Türkiye.
Yunus Murat AkcabelenDepartment of Pediatric Hematology and Oncology, Ankara Bilkent City Hospital, Ankara, Türkiye.
Nese YaraliDepartment of Pediatric Hematology and Oncology, Ankara Bilkent City Hospital, Ankara, Türkiye.
Namik Yasar OzbekDepartment of Pediatric Hematology and Oncology, Ankara Bilkent City Hospital, Ankara, Türkiye.
Ikbal Ok BozkayaDepartment of Pediatric Hematology and Oncology, Ankara Bilkent City Hospital, Ankara, Türkiye.
Dilek KacarDepartment of Pediatric Hematology and Oncology, Ankara Bilkent City Hospital, Ankara, Türkiye.
Berk ErgunGENIVA Information Health Services Company, Istanbul, Türkiye.
Alper AkkusRare Diseases and Orphan Drugs Application and Research Center (ACURARE), Rare Diseases and Orphan Drugs Application and Research Center (ACURARE), Acıbadem University, Istanbul, Türkiye.
Davut AlbayrakDepartment of Pediatric Hematology, Samsun Medical Park Hospital, Samsun, Türkiye.
Elif InceDepartment of Pediatric Hematology and Oncology, Faculty of Medicine, Ankara University, Ankara, Türkiye.
Ugur DemirsoyDepartment of Pediatric Oncology, Faculty of Medicine, Kocaeli University, Izmit, Kocaeli, Türkiye.
Gul Nihal OzdemirDepartment of Pediatric Hematology, Faculty of Medicine, Istinye University, Istanbul, Türkiye.
Omer DogruDepartment of Pediatric Hematology, Biruni University, Istanbul, Türkiye.
Seda ArasDepartment of Pediatric Hematology Oncology, Hatay Training and Research Hospital, Hatay, Türkiye.
Eylul AydinRare Diseases and Orphan Drugs Application and Research Center (ACURARE), Rare Diseases and Orphan Drugs Application and Research Center (ACURARE), Acıbadem University, Istanbul, Türkiye.
Busra UnalDepartment of Cancer Genetics, Umraniye Traning and Research Hospital, Istanbul, Türkiye.
Ufuk AmanvermezRare Diseases and Orphan Drugs Application and Research Center (ACURARE), Rare Diseases and Orphan Drugs Application and Research Center (ACURARE), Acıbadem University, Istanbul, Türkiye.
Ozlem Akgun DoganRare Diseases and Orphan Drugs Application and Research Center (ACURARE), Rare Diseases and Orphan Drugs Application and Research Center (ACURARE), Acıbadem University, Istanbul, Türkiye.
Sezer AkyoneyDepartment of Bioinformatics and Biostatistic, Institute of Health Sciences, Acıbadem Mehmet Ali Aydınlar University, Istanbul, Türkiye.
Muge SayitogluDepartment of Genetics, Istanbul University, Institute of Aziz Sancar Experimental Medicine, Istanbul, Türkiye.
Ann NordgrenDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Nihat Bugra AgaogluDepartment of Cancer Genetics, Umraniye Traning and Research Hospital, Istanbul, Türkiye.
Ugur OzbekRare Diseases and Orphan Drugs Application and Research Center (ACURARE), Rare Diseases and Orphan Drugs Application and Research Center (ACURARE), Acıbadem University, Istanbul, Türkiye.
Ozden Hatirnaz NgRare Diseases and Orphan Drugs Application and Research Center (ACURARE), Rare Diseases and Orphan Drugs Application and Research Center (ACURARE), Acıbadem University, Istanbul, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Leukemia is the most common cancer in children, and 10%-15% of patients with leukemia/lymphoma carry pathogenic germline cancer-predisposing variants. Identifying these variants is critical for understanding the genetic predisposition and optimizing clinical management. Methods: We performed germline short-read sequencing in 36 individuals from 20 families with suspected leukemia/lymphoma predisposition, including 20 index cases, 9 affected relatives, and 7 unaffected members. Results: We identified 13 clinically relevant germline variants in known cancer predisposition genes including Conclusion: These findings emphasize the clinical utility of germline testing in pediatric hematologic cancers by providing novel insights into the predisposition to leukemia/lymphoma and contributing to treatment regimens, donor selection, and diagnostic refinement, particularly in populations with high consanguinity.

Indexed as

cancer predispositionchildhood leukemiachildhood lymphomagermline variantsshort-read sequencing

Identifiers

PMID40995433
PMCPMC12454056

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.